JP2022537824A5 - - Google Patents

Info

Publication number
JP2022537824A5
JP2022537824A5 JP2021576275A JP2021576275A JP2022537824A5 JP 2022537824 A5 JP2022537824 A5 JP 2022537824A5 JP 2021576275 A JP2021576275 A JP 2021576275A JP 2021576275 A JP2021576275 A JP 2021576275A JP 2022537824 A5 JP2022537824 A5 JP 2022537824A5
Authority
JP
Japan
Prior art keywords
antigen
receptor
amino acid
cancer
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537824A (ja
JP7651481B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/039673 external-priority patent/WO2020264200A1/en
Publication of JP2022537824A publication Critical patent/JP2022537824A/ja
Publication of JP2022537824A5 publication Critical patent/JP2022537824A5/ja
Priority to JP2025040192A priority Critical patent/JP2025106277A/ja
Application granted granted Critical
Publication of JP7651481B2 publication Critical patent/JP7651481B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576275A 2019-06-26 2020-06-25 Cd3抗原結合断片およびそれを含む組成物 Active JP7651481B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025040192A JP2025106277A (ja) 2019-06-26 2025-03-13 Cd3抗原結合断片およびそれを含む組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866746P 2019-06-26 2019-06-26
US62/866,746 2019-06-26
US202063041059P 2020-06-18 2020-06-18
US63/041,059 2020-06-18
PCT/US2020/039673 WO2020264200A1 (en) 2019-06-26 2020-06-25 Cd3 antigen binding fragments and compositions comprising same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025040192A Division JP2025106277A (ja) 2019-06-26 2025-03-13 Cd3抗原結合断片およびそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2022537824A JP2022537824A (ja) 2022-08-30
JP2022537824A5 true JP2022537824A5 (cg-RX-API-DMAC7.html) 2023-06-30
JP7651481B2 JP7651481B2 (ja) 2025-03-26

Family

ID=74059962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576275A Active JP7651481B2 (ja) 2019-06-26 2020-06-25 Cd3抗原結合断片およびそれを含む組成物
JP2025040192A Pending JP2025106277A (ja) 2019-06-26 2025-03-13 Cd3抗原結合断片およびそれを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025040192A Pending JP2025106277A (ja) 2019-06-26 2025-03-13 Cd3抗原結合断片およびそれを含む組成物

Country Status (18)

Country Link
US (2) US20230121775A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990497A4 (cg-RX-API-DMAC7.html)
JP (2) JP7651481B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038068A (cg-RX-API-DMAC7.html)
CN (1) CN115175933A (cg-RX-API-DMAC7.html)
AU (1) AU2020308868A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143519A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003448A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000406A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210628A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000264A (cg-RX-API-DMAC7.html)
EC (1) ECSP22005986A (cg-RX-API-DMAC7.html)
IL (1) IL289102A (cg-RX-API-DMAC7.html)
MX (1) MX2021015880A (cg-RX-API-DMAC7.html)
PE (1) PE20220600A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500051A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020264200A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
PH12022553407A1 (en) * 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4058474B1 (en) * 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
CN117616137A (zh) * 2021-05-11 2024-02-27 佳努克斯治疗公司 靶向egfr和cd3的抗体及其用途
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
EP4433096A1 (en) * 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
CN116724057A (zh) * 2022-11-28 2023-09-08 浙江时迈药业有限公司 蛋白酶可切割的重组双特异性抗体和组合物及其用途
JP7855148B2 (ja) 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ, インコーポレイテッド 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
US20240400696A1 (en) 2023-04-17 2024-12-05 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
KR20260114559A (ko) 2023-12-08 2026-07-22 아뮤닉스 파마슈티컬스, 인크. 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법
CN120230203A (zh) * 2023-12-28 2025-07-01 四川思柏沃生物技术有限公司 抗cd3抗体及其用途
WO2025220804A1 (ko) * 2024-04-18 2025-10-23 주식회사 큐로셀 Cd5에 대한 신규 항체 및 이의 용도
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
WO2026136923A1 (en) * 2024-12-20 2026-06-25 Vir Biotechnology, Inc. Therapeutic uses of her-2 targeted bispecific polypeptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2193149A1 (en) 2007-10-02 2010-06-09 Merck Patent GmbH Crystalline egfr - matuzumab complex and matuzumab mimetics obtained thereof
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
EP4058466A1 (en) * 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Similar Documents

Publication Publication Date Title
AU2023229555B2 (en) CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP7148539B2 (ja) 免疫抱合体
TWI890655B (zh) 改良之抗原結合受體
JP7857236B2 (ja) 免疫活性化Fcドメイン結合分子
US12522638B2 (en) IL12 receptor agonists and methods of use thereof
CN115023444A (zh) 新型il2激动剂及其使用方法
CN112638950B (zh) 一种双特异性抗体
EP3990497A1 (en) Cd3 antigen binding fragments and compositions comprising same
WO2023045977A1 (zh) 白介素2突变体以及其融合蛋白
KR20180057720A (ko) 다가 Fv 항체
JP2023512452A (ja) Bcma指向性細胞免疫療法組成物および方法
CN117836328A (zh) 一种多特异性抗原结合蛋白及其应用
JP2022553292A5 (cg-RX-API-DMAC7.html)
WO2022148853A1 (en) Immunoconjugates
JP2024537096A (ja) がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
CN115052897B (zh) PLAP-CD3ε双特异性抗体
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
US20250333464A1 (en) Il10 agonists and methods of use thereof
CN118726265A (zh) 自分泌多特异性纳米抗体的工程化免疫细胞
US20250115657A1 (en) Bispecific FC Fusion Proteins with sPD-1 and IL-15
CN120826234A (zh) 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
RU2022101308A (ru) Антигенсвязывающие фрагменты для cd3 и композиции, содержащие их
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof
US20240270836A1 (en) Il12 receptor agonists and methods of use thereof
WO2025064716A1 (en) T-cell modulatory polypeptides and methods of use thereof